Ascendis Pharma/$ASND
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ascendis Pharma
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
Ticker
$ASND
Sector
Primary listing
Employees
1,017
Headquarters
Hellerup, Denmark
Website
Ascendis Pharma Metrics
BasicAdvanced
$12B
-
-$5.36
0.40
-
Price and volume
Market cap
$12B
Beta
0.4
52-week high
$208.16
52-week low
$114.53
Average daily volume
499K
Financial strength
Current ratio
1.019
Quick ratio
0.658
Long term debt to equity
-176.032
Total debt to equity
-422.523
Interest coverage (TTM)
-2.99%
Profitability
EBITDA (TTM)
-291.682
Gross margin (TTM)
84.88%
Net profit margin (TTM)
-55.25%
Operating margin (TTM)
-51.66%
Effective tax rate (TTM)
-2.66%
Revenue per employee (TTM)
$563,170
Management effectiveness
Return on assets (TTM)
-17.17%
Return on equity (TTM)
106.60%
Valuation
Price to revenue (TTM)
20.195
Price to book
-63.14
Price to tangible book (TTM)
-61.89
Price to free cash flow (TTM)
-57.994
Free cash flow yield (TTM)
-1.72%
Free cash flow per share (TTM)
-3.372
Growth
Revenue change (TTM)
54.50%
Earnings per share change (TTM)
-47.07%
3-year revenue growth (CAGR)
195.60%
10-year revenue growth (CAGR)
47.45%
3-year earnings per share growth (CAGR)
-13.38%
10-year earnings per share growth (CAGR)
14.37%
What the Analysts think about Ascendis Pharma
Analyst ratings (Buy, Hold, Sell) for Ascendis Pharma stock.
Bulls say / Bears say
Ascendis reported Q2 2025 revenue of €158.0 million, a 339% year-over-year increase driven by YORVIPATH (€103.0 million) and SKYTROFA (€50.7 million), underscoring rapid commercial traction (Investing.com).
The FDA accepted Ascendis’s TransCon CNP NDA for Priority Review with a PDUFA goal date of November 30, 2025, reflecting regulatory confidence in its potential as a best-in-class achondroplasia therapy (GlobeNewswire).
Interim Week 26 results from the Phase 2 COACH trial showed that TransCon CNP plus TransCon hGH combination therapy achieved mean annualized growth velocity exceeding the 97th percentile of average-stature children, validating the TransCon platform’s clinical differentiation (GlobeNewswire).
Despite strong sales growth, Ascendis Pharma reported a net loss of €38.9 million in Q2 2025 with operating expenses of €179.5 million, reflecting continued high R&D and SG&A burn that may delay cash-flow breakeven (GlobeNewswire).
As of June 30, 2025, Ascendis held €494 million in cash and equivalents, down from €560 million at year-end 2024, while funding costly late-stage trials and commercial expansion, raising concerns about its cash runway beyond mid-2026 (GlobeNewswire).
BioMarin’s June 12, 2025 Citizen Petition to the FDA requesting delay of CNP analog approvals until orphan exclusivities expire introduces potential regulatory headwinds and litigation risks that could slow TransCon CNP’s approval (SEC 6-K).
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
Ascendis Pharma Financial Performance
Revenues and expenses
Ascendis Pharma Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ascendis Pharma stock?
Ascendis Pharma (ASND) has a market cap of $12B as of September 16, 2025.
What is the P/E ratio for Ascendis Pharma stock?
The price to earnings (P/E) ratio for Ascendis Pharma (ASND) stock is 0 as of September 16, 2025.
Does Ascendis Pharma stock pay dividends?
No, Ascendis Pharma (ASND) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Ascendis Pharma dividend payment date?
Ascendis Pharma (ASND) stock does not pay dividends to its shareholders.
What is the beta indicator for Ascendis Pharma?
Ascendis Pharma (ASND) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.